HMC+ Exit

Production of chitin and chitosan-based high purity biopolymers. HMC develops new chitosan applications for the pharmaceutical industry, nanoparticles for drug delivery systems, and is a custom manufacturer of chitosan derivatives.

Press releases

Press
27. October 2010
Second financing round for Heppe Medical Chitosan GmbH with KI Kapital and High-Tech Gründerfonds
The latest investment will be used by Heppe Medical Chitosan GmbH (HMC+) to enlarge the marketing and sales force worldwide. HMC+ is an innovative developer and producer of pure biopolymers and nanoparticles based on chitin and chitosan. Heppe Medical Chitosan GmbH produces pure chitin, chitosan und derivates for the cosmetics and pharmaceutical industry under GMP (Good Manufacturing Practice) conditions. The cationic polymer chitosan is most suitable for applications in the above mentioned
 

Info & Contact

Address

Heinrich-Damerow-Straße 1
06120 Halle (Saale)

In portfolio

03. Jun 2008 – 23. Jun 2020

HTGF Manager

 
Ulrike Kalapis, Investment Manager
Exit